Join
Live feed
·
PRReleasevia Quantisnow
Alvotech logo

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

ByQuantisnow·Wall Street's wire, on your screen.
ALVO· Alvotech
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALVO (Alvotech) and more on Quantisnow.